Transparent by design
Follow the evidence.
Numbered sources connect the guide to the research behind it.
-
Source 1. Eli Lilly Australia / Medsinfo
Australian Product Information: Mounjaro (tirzepatide), vA13.0, September 2026 (opens in a new tab)
Australian prescribing source. Side-effect figures: section 4.8, Table 4 (p12), pooled SURMOUNT-1/2; trial context: section 5.1. vA13.0, September 2026; verify before publishing.
-
Source 2. Australian Commission on Safety and Quality in Health Care
Mounjaro KwikPen: Consumer Medicine Information (opens in a new tab)
Patient instructions, missed doses, device storage and adverse effects. Device details differ from single-dose presentations.
Accessed 3 October 2026Cited inTaking it week by weekIf you miss a doseSide effects: what to expectWhen to get help -
Source 3. Therapeutic Goods Administration
Updated contraception advice for Mounjaro (tirzepatide) (opens in a new tab)
1 December 2025. Non-oral contraception or added barrier protection during initiation and dose escalation.
Accessed 3 October 2026Cited inPregnancy and contraception -
Source 4. Therapeutic Goods Administration
Medicines containing GLP-1 and dual GIP/GLP-1 receptor agonists (opens in a new tab)
3 June 2025. Delayed gastric emptying and aspiration precautions around anaesthesia or deep sedation.
Accessed 3 October 2026Cited inImportant conversationsConnecting the pathways -
Source 5. Jastreboff et al. · New England Journal of Medicine, 2022
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) (opens in a new tab)
Randomised 72-week trial in 2,539 adults without diabetes. Industry funded. Group averages do not predict individual results.
Accessed 3 October 2026Cited inWhat can I expect?Read the outcome in context -
Source 6. Aronne et al. · JAMA, 2024
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4) (opens in a new tab)
Randomised withdrawal trial after an initial treatment period. Supports discussion of ongoing treatment; selected trial population.
Accessed 3 October 2026Cited inThink beyond the first few monthsRead the outcome in context -
Source 7. Willard et al. · JCI Insight, 2020
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (opens in a new tab)
Original receptor pharmacology research. Cell and preclinical findings are not proof of each pathway's clinical contribution.
Accessed 3 October 2026Cited inHow it worksOne molecule, two receptorsConnecting the pathwaysKeep mechanism and safety claims proportionate -
Source 8. Eli Lilly Australia
Mounjaro: dosing (opens in a new tab)
Manufacturer patient resource for gradual dose escalation. Commercial source; interpreted alongside the Australian PI.
Accessed 3 October 2026Cited inTaking it week by week -
Source 9. Eli Lilly Australia
Mounjaro: side effects (opens in a new tab)
Manufacturer advice on smaller meals and tolerability. Commercial source; does not replace clinical assessment.
Accessed 3 October 2026Cited inSide effects: what to expect -
Source 10. Therapeutic Goods Administration
GLP-1 RAs: warnings aligned over potential risk of suicidal thoughts or behaviours (opens in a new tab)
1 December 2025. Precautionary monitoring advice; reports do not establish that the medicine causes these symptoms.
Accessed 3 October 2026Cited inWhen to get helpKeep mechanism and safety claims proportionate -
Source 11. Therapeutic Goods Administration
GLP-1 RAs and rare vision disorder (opens in a new tab)
2026 class warning. Evidence differs between medicines; urgent assessment is advised for sudden vision loss.
Accessed 3 October 2026Cited inWhen to get helpKeep mechanism and safety claims proportionate